There Is Nothing Like 4D Molecular Therapeutics Inc (FDMT) Stock

Barclays raised the price target for the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) stock to “an Overweight”. The rating was released on April 15, 2024, according to finviz. The research report from Goldman has resumed the stock to Buy, with a price target set at $81. The stock was initiated by RBC Capital Mkts, who disclosed […]

4D Molecular Therapeutics Inc (FDMT) Stock is more thoughtful than you think

Goldman raised the price target for the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) stock to “a Buy”. The rating was released on February 07, 2024, according to finviz. The research report from Cantor Fitzgerald has initiated the stock to Overweight, with a price target set at $32. The stock was upgraded by Leerink Partners, who disclosed […]

Growing at an Unbelievable Rate: 4D Molecular Therapeutics Inc (FDMT) Stock

Goldman raised the price target for the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) stock to “a Buy”. The rating was released on February 07, 2024, according to finviz. The research report from Cantor Fitzgerald has initiated the stock to Overweight, with a price target set at $32. The stock was upgraded by Leerink Partners, who disclosed […]

Is 4D Molecular Therapeutics Inc (FDMT) Stock worth its current valuation?

Goldman raised the price target for the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) stock to “a Buy”. The rating was released on February 07, 2024, according to finviz. The research report from Cantor Fitzgerald has initiated the stock to Overweight, with a price target set at $32. The stock was upgraded by Leerink Partners, who disclosed […]